Zacks Investment Research upgraded shares of OncoCyte (NYSEAMERICAN:OCX) from a hold rating to a buy rating in a report issued on Tuesday morning. The brokerage currently has $2.00 target price on the biotechnology company’s stock.
According to Zacks, “OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. “
Separately, MED began coverage on OncoCyte in a report on Monday, October 29th. They set a positive rating on the stock.
OncoCyte (NYSEAMERICAN:OCX) last announced its quarterly earnings results on Tuesday, November 13th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.02.
OncoCyte Company Profile
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer.
See Also: Intrinsic Value
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for OncoCyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OncoCyte and related companies with MarketBeat.com's FREE daily email newsletter.